GREN yields 20000000.00% · ABBV yields 3.12%● Live data
📍 GREN pulled ahead of the other in Year 1
Combined, GREN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GREN + ABBV for your $10,000?
In June 2003, AgroCan Corporation changed its name to Greensmart Corporation in connection with an asset acquisition agreement with Winsmart Development, Ltd. According to the basic terms of the agreement, the company would issue to Winsmart 29,868,737 shares of its common stock. Also, Winsmart would sell to the company approximately 553,212 young eucalyptus trees planted in a total of 340 leased hectares; and a tree seedling and nursery farm situated on 3.3 leased hectares. Greensmart Corporation, through its subsidiary, AgroCan (China), Inc., specializes in producing compound fertilizers, which are custom-made to suit local conditions, such as plant, soil, and climate. Compound fertilizers are the end product made from the combination of the three primary nutrients: nitrogen, phosphate, and potassium, together with other elements, such as iron, zinc, copper, and manganese. These elements are blended in different proportions, and are made into pellets and packed into bags. Fertilizer applications include mainly paddy rice, wheat, corn, sugar cane, tobacco, cotton, vegetables, tree plantation, and fruit trees. The company's fertilizers are sold under the brand name 'AgroCan Three Leaves'. Its main customers for the fertilizers comprise the farming supply bureaus and cooperatives under the State Internal Trade Bureau of the People's Republic of China. These entities act as wholesalers to individual farmers. State-owned farms and plantations are also major accounts of the company. Greensmart Corporation was founded in 1996 and is based in Kwun Tong, Hong Kong.
Full GREN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.